{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:47:35Z","timestamp":1787496455929,"version":"build-2736575974"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jad.2021.03.062","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T21:02:06Z","timestamp":1616792526000},"page":"316-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["In schizophrenia, immune-inflammatory pathways are strongly associated with depressive and anxiety symptoms, which are part of a latent trait which comprises neurocognitive impairments and schizophrenia symptoms."],"prefix":"10.1016","volume":"287","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7667-6731","authenticated-orcid":false,"given":"Abbas F.","family":"Almulla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid F.","family":"Al-Rawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein Kadhem","family":"Al-Hakeim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2021.03.062_bib0001","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/schbul\/sbp148","article-title":"How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association","volume":"37","author":"Achim","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2021.03.062_bib0002","first-page":"1","article-title":"High mobility group protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations with Interleukin-6, Symptom Domains, and Neurocognitive Impairments","volume":"46","author":"Al-Dujaili","year":"2020","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2021.03.062_bib0003","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2174\/1568026620666200128143948","article-title":"Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia","volume":"20","author":"Al-Hakeim","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.jad.2021.03.062_bib0004","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.schres.2020.05.003","article-title":"Chronic fatigue and fibromyalgia symptoms are key components of deficit schizophrenia and are strongly associated with activated immune-inflammatory pathways","volume":"222","author":"Almulla","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2021.03.062_bib0005","first-page":"1","article-title":"Schizophrenia phenomenology revisited: positive and negative symptoms are strongly related reflective manifestations of an underlying single trait indicating overall severity of schizophrenia","volume":"25","author":"Almulla","year":"2020","journal-title":"CNS Spectr"},{"key":"10.1016\/j.jad.2021.03.062_bib0006","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pnpbp.2012.07.016","article-title":"Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways","volume":"42","author":"Anderson","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0007","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.schres.2016.12.021","article-title":"Childhood trauma, depression and negative symptoms are independently associated with impaired quality of life in schizophrenia. Results from the national FACE-SZ cohort","volume":"185","author":"Andrianarisoa","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2021.03.062_bib0008","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/jcbfm.2013.213","article-title":"The Wnt\/planar cell polarity signaling pathway contributes to the integrity of tight junctions in brain endothelial cells","volume":"34","author":"Artus","year":"2014","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jad.2021.03.062_bib0009","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B Methodol"},{"key":"10.1016\/j.jad.2021.03.062_bib0010","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jad.2009.03.017","article-title":"Depression, traumatic stress and interleukin 6","volume":"120","author":"Bob","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.03.062_bib0011","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/1039856215588207","article-title":"How should we manage anxiety in patients with schizophrenia?","volume":"23","author":"Bosanac","year":"2015","journal-title":"Australas. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2013.07.030","article-title":"Anxiety comorbidity in schizophrenia","volume":"210","author":"Braga","year":"2013","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.jad.2021.03.062_bib0013","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1176\/jnp.2008.20.4.431","article-title":"Depression in schizophrenia: methodological artifact or distinct feature of the illness?","volume":"20","author":"Chemerinski","year":"2008","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2021.03.062_bib0014","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/0004867414533012","article-title":"Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries","volume":"48","author":"Davis","year":"2014","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0015","first-page":"1","article-title":"Psychotic Depression: Diagnosis, Differential Diagnosis, and Treatment","author":"Dubovsky","year":"2020","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2021.03.062_bib0016","first-page":"5","article-title":"Automated neuropsychological test battery in depression\u2013preliminary data","volume":"15","author":"Egerhazi","year":"2013","journal-title":"Neuropsychopharmacol. Hung."},{"key":"10.1016\/j.jad.2021.03.062_bib0017","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4088\/JCP.v60n1105","article-title":"Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder","volume":"60","author":"Emsley","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0018","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1192\/bjp.2018.87","article-title":"Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort","volume":"213","author":"Fond","year":"2018","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0019","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamapsychiatry.2013.269","article-title":"The psychosis high-risk state: a comprehensive state-of-the-art review","volume":"70","author":"Fusar-Poli","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151648","article-title":"The Positive and Negative Syndrome Scale (PANSS): A three-factor model of psychopathology in marginally housed persons with substance dependence and psychiatric illness","volume":"11","author":"Giesbrecht","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2021.03.062_bib0021","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12991-015-0068-9","article-title":"The role of cognitive dysfunction in the symptoms and remission from depression","volume":"14","author":"Gonda","year":"2015","journal-title":"Ann. Gen. psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0022","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0920-9964(01)00373-5","article-title":"Panic attacks in schizophrenia","volume":"58","author":"Goodwin","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2021.03.062_bib0023","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1590\/S1516-44462012000100013","article-title":"Peripheral chemokine levels in women with recurrent major depression with suicidal ideation","volume":"34","author":"Grassi-Oliveira","year":"2012","journal-title":"Braz. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0024","series-title":"CGI. clinical global impressions. ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.jad.2021.03.062_bib0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.jad.2021.03.062_bib0026","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0027","first-page":"575","article-title":"Depression in schizophrenia: associations with cognition, functional capacity, everyday functioning, and self-assessment","volume":"43","author":"Harvey","year":"2017","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2021.03.062_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-018-0102-1","article-title":"Exploring the Wnt signaling pathway in schizophrenia and bipolar disorder","volume":"8","author":"Hoseth","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0029","article-title":"CCL11 or eotaxin-1: An immune marker for ageing and accelerated ageing in neuro-psychiatric disorders","volume":"2020","author":"Ivanovska","year":"2020","journal-title":"Preprints"},{"key":"10.1016\/j.jad.2021.03.062_bib0030","first-page":"1","article-title":"Epidemiology and risk factors of schizophrenia","volume":"37","author":"Janoutov\u00e1","year":"2016","journal-title":"Neuroendocrinol. Lett."},{"key":"10.1016\/j.jad.2021.03.062_bib0031","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1007\/s12035-017-0751-8","article-title":"Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia","volume":"55","author":"Kanchanatawan","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jad.2021.03.062_bib0032","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.pnpbp.2017.06.033","article-title":"Depressive, anxiety and hypomanic symptoms in schizophrenia may be driven by tryptophan catabolite (TRYCAT) patterning of IgA and IgM responses directed to TRYCATs","volume":"80","author":"Kanchanatawan","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0033","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s12035-017-0417-6","article-title":"Deficit, but not nondeficit, schizophrenia is characterized by mucosa-associated activation of the tryptophan catabolite (TRYCAT) pathway with highly specific increases in IgA responses directed to picolinic, xanthurenic, and quinolinic acid","volume":"55","author":"Kanchanatawan","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jad.2021.03.062_bib0034","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s11011-017-9982-7","article-title":"Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway","volume":"32","author":"Kanchanatawan","year":"2017","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.jad.2021.03.062_bib0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11011-018-0339-7","article-title":"Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia","volume":"34","author":"Kanchanatawan","year":"2019","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.jad.2021.03.062_bib0036","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.pnpbp.2017.06.031","article-title":"Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition","volume":"80","author":"Kanchanatawan","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0037","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s12640-018-9868-4","volume":"33","author":"Kanchanatawan","year":"2018","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.jad.2021.03.062_bib0038","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2021.03.062_bib0039","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","article-title":"The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery","volume":"68","author":"Keefe","year":"2004","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.jad.2021.03.062_bib0040","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/schbul\/sbq059","article-title":"The brief negative symptom scale: psychometric properties","volume":"37","author":"Kirkpatrick","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jad.2021.03.062_bib0041","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2016.05.003","article-title":"Secondary negative symptoms - A review of mechanisms, assessment and treatment","volume":"186","author":"Kirschner","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2021.03.062_bib0042","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1523\/JNEUROSCI.4458-07.2008","article-title":"The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system","volume":"28","author":"Land","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jad.2021.03.062_bib0043","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1083\/jcb.200806024","article-title":"Wnt\/\u03b2-catenin signaling controls development of the blood\u2013brain barrier","volume":"183","author":"Liebner","year":"2008","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jad.2021.03.062_bib0044","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neuint.2014.05.004","article-title":"Dysfunctional Wnt\/\u03b2-catenin signaling contributes to blood\u2013brain barrier breakdown in Alzheimer's disease","volume":"75","author":"Liu","year":"2014","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.jad.2021.03.062_bib0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.schres.2005.07.005","article-title":"Association of neurocognition, anxiety, positive and negative symptoms with coping preference in schizophrenia spectrum disorders","volume":"80","author":"Lysaker","year":"2005","journal-title":"Schizophr. Res."},{"issue":"12","key":"10.1016\/j.jad.2021.03.062_bib0046","doi-asserted-by":"crossref","first-page":"8885","DOI":"10.1007\/s12035-018-1016-x","article-title":"The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder","volume":"55","author":"Maes","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jad.2021.03.062_bib0047","doi-asserted-by":"crossref","unstructured":"Maes, M., Kanchanatawan, B., 2020. A Generalized Cognitive Decline (GCoDe) Partly Mediates the Effects of Neuro-Immune and Neuro-Oxidative Toxicity on the Symptomatome and Lowered Quality of Life in (Deficit) Schizophrenia. Preprints 2020110523 (doi: 10.20944\/preprints202011.0523.v1). .","DOI":"10.20944\/preprints202011.0523.v1"},{"key":"10.1016\/j.jad.2021.03.062_bib0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000284842","article-title":"Evidence for the existence of major depression with and without anxiety features","volume":"27","author":"Maes","year":"1994","journal-title":"Psychopathology"},{"key":"10.1016\/j.jad.2021.03.062_bib0049","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0165-0327(95)00028-L","article-title":"Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression","volume":"34","author":"Maes","year":"1995","journal-title":"J. Affective Disord."},{"key":"10.1016\/j.jad.2021.03.062_bib0050","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0006-3223(98)00131-0","article-title":"Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events","volume":"45","author":"Maes","year":"1999","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0051","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11011-012-9316-8","article-title":"IgM-mediated autoimmune responses directed against anchorage epitopes are greater in Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome (ME\/CFS) than in major depression","volume":"27","author":"Maes","year":"2012","journal-title":"Metab. Brain. Dis."},{"key":"10.1016\/j.jad.2021.03.062_bib0052","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000336803","article-title":"Inflammatory and cell-mediated immune biomarkers in myalgic encephalomyelitis\/chronic fatigue syndrome and depression: inflammatory markers are higher in myalgic encephalomyelitis\/chronic fatigue syndrome than in depression","volume":"81","author":"Maes","year":"2012","journal-title":"Psychother. Psychosom."},{"issue":"9","key":"10.1016\/j.jad.2021.03.062_bib0053","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1007\/s12035-019-1552-z","article-title":"Development of a Novel Staging Model for Affective Disorders Using Partial Least Squares Bootstrapping: Effects of Lipid-Associated Antioxidant Defenses and Neuro-Oxidative Stress","volume":"56","author":"Maes","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jad.2021.03.062_bib0054","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1515\/bmc-2019-0023","article-title":"Schizophrenia phenomenology comprises a bifactorial general severity and a single-group factor, which are differently associated with neurotoxic immune and immune-regulatory pathways","volume":"10","author":"Maes","year":"2019","journal-title":"Biomol. Concepts"},{"key":"10.1016\/j.jad.2021.03.062_bib0055","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1007\/s12035-020-02047-5","article-title":"Lowered Antioxidant Defenses and Increased Oxidative Toxicity Are Hallmarks of Deficit Schizophrenia: A Nomothetic Network Psychiatry Approach","volume":"57","author":"Maes","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jad.2021.03.062_bib0056","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/brainsci10090645","article-title":"How to construct a bottom-up nomothetic network model and disclose novel nosological classes by integrating risk resilience and adverse outcome pathways with the phenome of schizophrenia","volume":"10","author":"Maes","year":"2020","journal-title":"Brain Sci"},{"key":"10.1016\/j.jad.2021.03.062_bib0057","volume":"6","author":"Maes","year":"2021","journal-title":"Mol. Neurobiol. Mar"},{"key":"10.1016\/j.jad.2021.03.062_bib0058","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jpsychires.2013.10.007","article-title":"Peripheral eotaxin-1 (CCL11) levels and mood disorder diagnosis in a population-based sample of young adults","volume":"48","author":"Magalhaes","year":"2014","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2021.03.062_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2020.104881","article-title":"Dickkopf-related protein-1 inhibition attenuates amyloid-beta pathology associated to Alzheimer's disease","volume":"141","author":"Menet","year":"2020","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.jad.2021.03.062_bib0060","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12888-016-0815-8","article-title":"Neurocognitive profile in major depressive disorders: relationship to symptom level and subjective memory complaints","volume":"16","author":"Mohn","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0061","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.schres.2019.06.022","article-title":"Post-psychotic depression: Paranoia and the damage done","volume":"211","author":"Moritz","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jad.2021.03.062_bib0062","first-page":"150","article-title":"Attention and memory deficits in schizophrenia: the role of symptoms of depression","volume":"19","author":"M\u00f6ser","year":"2006","journal-title":"Cogn. Behav. Neurol."},{"key":"10.1016\/j.jad.2021.03.062_bib0063","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11011-020-00619-x","article-title":"Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenome of schizophrenia: neuro-immune and opioid system correlates","volume":"36","author":"Mousa","year":"2021","journal-title":"Metabol. Brain Dis."},{"key":"10.1016\/j.jad.2021.03.062_bib0064","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3390\/diagnostics10090633","article-title":"The Endogenous Opioid System in Schizophrenia and Treatment Resistant Schizophrenia: Increased Plasma Endomorphin 2, and \u03ba and \u03bc Opioid Receptors Are Associated with Interleukin-6","volume":"10","author":"Moustafa","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jad.2021.03.062_bib0065","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1590\/1980-57642015dn93000012","article-title":"Executive functions as a potential neurocognitive endophenotype in anxiety disorders: A systematic review considering DSM-IV and DSM-5 diagnostic criteria classification","volume":"9","author":"Muller","year":"2015","journal-title":"Dement. Neuropsychol."},{"key":"10.1016\/j.jad.2021.03.062_bib0066","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1080\/10550490902925862","article-title":"The kappa-opiate receptor impacts the pathophysiology and behavior of substance use","volume":"18","author":"Mysels","year":"2009","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.jad.2021.03.062_bib0067","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1471-244X-14-166","article-title":"Severity of psychotic episodes in predicting concurrent depressive and anxiety features in acute phase schizophrenia","volume":"14","author":"Naidu","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0068","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-010-1834-7","article-title":"Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats","volume":"210","author":"Nemeth","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jad.2021.03.062_bib0069","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.biopsych.2018.09.030","article-title":"Interleukin-6 induced by social stress promotes a unique transcriptional signature in the monocytes that facilitate anxiety","volume":"85","author":"Niraula","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0070","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.psc.2017.08.005","article-title":"The Effect of Cognitive Behavioral Interventions on Depression and Anxiety Symptoms in Patients with Schizophrenia Spectrum Disorders: A Systematic Review","volume":"40","author":"Opoka","year":"2017","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.jad.2021.03.062_bib0071","first-page":"401","article-title":"Psychosis-related matricide associated with a lesion of the ventromedial prefrontal cortex","volume":"41","author":"Orellana","year":"2013","journal-title":"J. Am. Acad. Psychiatry Law"},{"key":"10.1016\/j.jad.2021.03.062_bib0072","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fpsyt.2013.00035","article-title":"Executive functioning in schizophrenia","volume":"4","author":"Orellana","year":"2013","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0073","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/jnc.12492","article-title":"HIV increases the release of dickkopf-1 protein from human astrocytes by a Cx43 hemichannel-dependent mechanism","volume":"128","author":"Orellana","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.jad.2021.03.062_bib0074","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.pnpbp.2012.10.017","article-title":"Antioxidants as potential therapeutics for neuropsychiatric disorders","volume":"46","author":"Pandya","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0075","first-page":"S179","article-title":"The relationship between depression and cognitive deficits","volume":"24","author":"Papazacharias","year":"2012","journal-title":"Psychiatr. Danub"},{"key":"10.1016\/j.jad.2021.03.062_bib0076","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1440-1819.2008.01844.x","article-title":"Cognitive functions in bipolar affective disorder and schizophrenia: comparison","volume":"62","author":"Pradhan","year":"2008","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2021.03.062_bib0077","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/NMD.0b013e3181c81fc0","article-title":"Depression and depressive symptoms in first episode psychosis","volume":"198","author":"Romm","year":"2010","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.jad.2021.03.062_bib0078","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s12035-019-01737-z","article-title":"The role of aberrations in the immune-inflammatory response system (IRS) and the compensatory immune-regulatory reflex system (CIRS) in different phenotypes of schizophrenia: the IRS-CIRS theory of schizophrenia","volume":"57","author":"Roomruangwong","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jad.2021.03.062_bib0079","first-page":"1218","article-title":"The role of interleukin-6 signaling in nervous tissue","volume":"1863","author":"Rothaug","year":"2016","journal-title":"BBA-Mol. Cell. Res."},{"key":"10.1016\/j.jad.2021.03.062_bib0080","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1503\/jpn.180081","article-title":"Social anxiety disorder in schizophrenia: a neglected, yet potentially important comorbidity","volume":"43","author":"Roy","year":"2018","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.jad.2021.03.062_bib0081","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/08039480801984008","article-title":"Early detection and intervention of psychosis. A review","volume":"62","author":"Salokangas","year":"2008","journal-title":"Nord. J Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0082","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.biopsych.2019.08.004","article-title":"Role of kappa opioid receptors in symptoms of schizophrenia: What Is the Neurobiology?","volume":"86","author":"Shekhar","year":"2019","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0083","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s12640-019-00126-7","article-title":"Increased Serum Immunoglobulin Responses to Gut Commensal Gram-Negative Bacteria in Unipolar Major Depression and Bipolar Disorder Type 1, Especially When Melancholia Is Present","volume":"37","author":"Simeonova","year":"2020","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.jad.2021.03.062_bib0084","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.euroneuro.2007.06.004","article-title":"A detailed examination of cytokine abnormalities in major depressive disorder","volume":"18","author":"Simon","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2021.03.062_bib0085","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/1871527317666181119115532","article-title":"A dew schizophrenia model: immune activation is associated with the induction of Different neurotoxic products which together determine memory impairments and schizophrenia symptom dimensions","volume":"18","author":"Sirivichayakul","year":"2019","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.jad.2021.03.062_bib0086","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0306-9877(95)90062-4","article-title":"The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence","volume":"45","author":"Smith","year":"1995","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.jad.2021.03.062_bib0087","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1590\/1516-4446-2012-0978","article-title":"Treatment of anxiety disorders by psychiatrists from the American Psychiatric Practice Research Network","volume":"35","author":"Sorsdahl","year":"2013","journal-title":"Braz. J. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0088","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0006-3223(00)00910-0","article-title":"Neuropsychologic impairments in bipolar and unipolar mood disorders on the CANTAB neurocognitive battery","volume":"48","author":"Sweeney","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0089","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fpsyt.2018.00241","article-title":"Revisiting the role of eotaxin-1\/CCL11 in psychiatric disorders","volume":"9","author":"Teixeira","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/S0033291700028105","article-title":"Time course of prefrontal lobe dysfunction in severely depressed in-patients: a longitudinal neuropsychological study","volume":"25","author":"Trichard","year":"1995","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2021.03.062_bib0091","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1600-0447.2009.01506.x","article-title":"The evolution of depression and suicidality in first episode psychosis","volume":"122","author":"Upthegrove","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2021.03.062_bib0092","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature10357","article-title":"The ageing systemic milieu negatively regulates neurogenesis and cognitive function","volume":"477","author":"Villeda","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jad.2021.03.062_bib0093","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.biopsych.2016.10.023","article-title":"Addressing cognitive deficits in schizophrenia: Toward a neurobiologically informed approach","volume":"81","author":"Walker","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2021.03.062_bib0094","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.neuroscience.2019.06.038","article-title":"Minocycline Preserves the Integrity and Permeability of BBB by Altering the Activity of DKK1\u2013Wnt Signaling in ICH Model","volume":"415","author":"Wang","year":"2019","journal-title":"Neurosci."},{"key":"10.1016\/j.jad.2021.03.062_bib0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jad.2003.10.009","article-title":"Evidence for continuing neuropsychological impairments in depression","volume":"82","author":"Weiland-Fiedler","year":"2004","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2021.03.062_bib0096","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fnins.2020.00115","article-title":"Rethinking schizophrenia and depression comorbidity as one psychiatric disorder entity: evidence from mouse model","volume":"14","author":"Zhou","year":"2020","journal-title":"Front. Neurosci."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032721002883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032721002883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:59:56Z","timestamp":1759024796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032721002883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":96,"alternative-id":["S0165032721002883"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2021.03.062","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In schizophrenia, immune-inflammatory pathways are strongly associated with depressive and anxiety symptoms, which are part of a latent trait which comprises neurocognitive impairments and schizophrenia symptoms.","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2021.03.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}